|
|
 |
|
Viewing report
|
|
|
|
Pharmaceutical Pricing and Reimbursement in Russia
Decision Resources, Inc., Dec 2009, Pages: 25
The Russian pharmaceutical market is attractive for several reasons: the economy has expanded rapidly, per capita gross national income is substantially greater than in most other emerging markets, the pharmaceutical market is maintaining double-digit growth rates, and consumers have a strong preference for familiar branded drugs. In addition, the Russian government appears to be increasingly aware of the importance of boosting state investment in healthcare. However, multinational companies will have to overcome substantial hurdles to capitalize on the opportunities that exist in the Russian pharmaceutical market.
Questions Answered in this Report:
- Russia faces severe public health challenges and the prospect of a long-term demographic crisis. What are the main causes of morbidity and mortality in Russia? How has life expectancy been affected by recent health problems? To what extent is the Russian population projected to decline, and how has the government responded?
- The Russian pharmaceutical market is overwhelmingly a cash market. What has been the impact of a drug reimbursement program for social security recipients? How significant is the private market? What plans does the government have to extend access to pharmaceutical reimbursement?
- The government is increasing its controls on pharmaceutical pricing. How is the government addressing pricing issues at the drug registration stage? What reforms are pending for imported and domestic drugs?
- The government recently signalled its intention to play a more active role in shaping the pharmaceutical market in the future. What is the government’s vision for the pharmaceutical industry to 2020? How does the government regard the role of foreign drug manufacturers? How will the launch of generic or biosimilar versions of 15 high-priced drugs be accelerated?
Scope:
- Demographic, socioeconomic, and health trends: population projections to 2050; life expectancy at birth; major causes of morbidity and mortality.
- Organization and funding of the healthcare system: public healthcare in the Soviet era; public healthcare reform in the post-Soviet era; private healthcare.
- Regulatory environment: drug licensing; intellectual property rights; counterfeiting.
- Pharmaceutical pricing and reimbursement: recent pricing trends; price-setting procedures; differential pricing for domestic and imported drugs; pending reforms.
- Pharmaceutical market trends: sales trends; market shares of imported and domestic drugs; role of foreign companies; impact of the Supplementary Pharmaceutical Provision (DLO) program.
- Outlook and implications for the pharmaceutical industry: key challenges for the pharmaceutical industry; proposal for a new pharmaceutical reimbursement program; government strategy for the pharmaceutical industry to 2020; plans to accelerate the launch of select generics/biosimilars; benefits of local manufacturing.
Customers who bought this item also bought
Pricing and Reimbursement in Russia - Big Pharma Take Advantage of Reimbursement for Costly Drugs Through the DLO’s Seven Nosologies Program
Russia Pharmaceutical Market Overview Pharma companies target Russia despite the challenges it presents
Pricing, Reimbursement, and Market Access in the BRIC-MT Markets
Strategic Analysis of the Russian Pharmaceutical Market
E7: The Outlook for Pharmaceuticals to 2012
Generic and Innovative Drugs Market in Russia and Ukraine 2011 - Comparative Analysis, Reimbursement Policies and Development Forecasts for 2011-2013
Italy Pharmaceutical Market Overview Generic penetration set to rise
The Pharmaceutical Market: Russia
Biosimilars: Current Situation & Future Prospects, Worldwide
Overview of Pharmaceutical and Medical Devices Industry in Russia and Other CIS Countries
|
|
|
|
